Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled gene therapy trial of PF-06939926 in ambulatory boys with Duchenne muscular dystrophy
MOH_2020-07-07_009124Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2020
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fordadistrogene movaparvovec in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in North Star Ambulatory Assessment total score. Started Jun 2020; status: recruiting.
02
Drugs
fordadistrogene movaparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2020-07-07_009124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-07_009124.